Drugs / TEV-56286
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07674940 | Jun 2026 → Jan 2027 expected | — | Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06911567 | Mar → May 2025 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06627231 | Oct → Nov 2024 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07197866 | Sep 2025 → May 2029 expected | multiple system atrophy | Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06568237 | Oct 2024 → Sep 2027 expected | multiple system atrophy | Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy tevapharm.com ↗
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy tevapharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEV-56286 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07674940 ↗ |
| Route | Oral | “TEV-56286 capsules administered orally” NCT06568237 ↗ |